

Adding ‘Respiratory Syncytial Virus (RSV) Hospitalizations and Deaths’ to the List of Reportable Diseases, Emergency Illnesses and Health Conditions

Respiratory syncytial virus (RSV) is an important cause of morbidity and mortality particularly for young children, older adults, and persons with underlying health conditions. Seasonal respiratory viral illnesses such as COVID-19, influenza, and RSV can be associated with severe outcomes, including hospitalizations and death. Having a mechanism in place to monitor trends in severe RSV disease is critical to guide public health messaging and decision making.

Effective October 1, 2023, pursuant to Section 19a-2a of the Connecticut General Statutes and Sections 19a-215 and 19a-36-A7 of the Regulations of Connecticut State Agencies, Manisha Juthani, MD, Commissioner of the Connecticut Department of Public Health (DPH) will amend the List of Reportable Diseases, Emergency Illnesses and Health Conditions to include RSV hospitalizations and deaths. COVID-19 and influenza hospitalizations and deaths are already reportable. Adding RSV hospitalizations and deaths to the list will provide a more comprehensive picture of severe respiratory viral outcomes.

Respiratory syncytial virus hospitalizations and deaths shall be a Category 2 condition and must be reported electronically or by fax within 12 hours. The DPH Reportable Disease Confidential Case Report Form PD-23 shall be used to collect initial information on cases where RSV is certified as the cause of death or a person is hospitalized with RSV. Completed PD-23 Case Report Forms may be reported by fax to (860) 920-3131.

INSIDE

Page

Adding ‘Respiratory Syncytial Virus (RSV) Hospitalizations and Deaths’ to the List of Reportable Diseases, Emergency Illnesses and Health Conditions	32
Updated List of Reportable Diseases, Emergency Illnesses and Health Conditions—2023	33
Updated List of Reportable Laboratory Findings—2023	34
Persons Required to Report Significant Findings	35

A hospital infection preventionist entering a case in the Connecticut Electronic Disease Surveillance System (CTEDSS) or reporting by electronic file also satisfies this reporting requirement and is the preferred method to receive these results. DPH will share the report with the local health department for the town where the case patient resides and will follow up with the provider as needed to collect additional information.

Healthcare providers can refer questions about RSV reporting to the DPH Epidemiology and Emerging Infections Program at (860) 509-7994 or DPH.eeip@ct.gov. Questions related to electronic disease reporting may be directed to DPH.InformaticsLab@ct.gov.

CONTACT INFORMATION

Connecticut Department of Public Health
Infectious Diseases Section
410 Capitol Avenue/MS#11FDS
Hartford, CT 06134
Phone: 860-509-7995
Fax: 860-509-7910

REPORTABLE DISEASES, EMERGENCY ILLNESSES and HEALTH CONDITIONS – 2023

PART A: REPORTABLE DISEASES

Physicians, and other professionals are required to report using the Reportable Disease Confidential Case Report form (PD-23), other disease specific form or authorized method (see page 4 for additional information). Forms can be found on the DPH ["Forms" webpage](#). Changes for 2023 are in **bold font**.

Category 1 Diseases: For diseases marked with a (☎) report to DPH at 860-509-7994 the day of recognition or strong suspicion. On evenings, weekends, and holidays call (860) 509-8000. A PD-23 must also be submitted within 12 hours.

Category 2 Diseases: All other diseases do not require a phone call but must be reported electronically or by fax within 12 hours. A hospital IP entering a case in CTEDSS (where applicable) satisfies the reporting requirement.

Acquired Immunodeficiency Syndrome (1,2)	Hepatitis B:	Powassan virus infection
Acute flaccid myelitis	▪ acute infection (2)	☎ Q fever
☎ HIV infection (Acute)	▪ HBsAg positive pregnant women	☎ Rabies
☎ Anthrax	Hepatitis C:	Respiratory Syncytial Virus (RSV) Death
Babesiosis	▪ acute infection (2)	RSV Hospitalization
<i>Borrelia miyamotoi</i> disease	▪ perinatal infection	☎ Ricin poisoning
☎ Botulism	▪ positive rapid antibody test result	Rocky Mountain spotted fever
☎ Brucellosis	HIV-1 / HIV-2 infection in: (1)	Rubella (including congenital)
California group arbovirus infection	▪ persons with active tuberculosis disease	Salmonellosis
Campylobacteriosis	▪ persons with a latent tuberculous	Shiga toxin-related disease (gastroenteritis)
<i>Candida auris</i>	infection (history or tuberculin skin test	Shigellosis
Chancroid	≥5mm induration by Mantoux	Silicosis
Chickenpox	technique)	☎ Smallpox
Chickenpox-related death	▪ persons of any age	St. Louis encephalitis virus infection
Chikungunya	▪ pregnant women	☎ Staphylococcal enterotoxin B pulmonary
Chlamydia (<i>C. trachomatis</i>) (all sites)	HPV: biopsy proven CIN 2, CIN 3 or AIS	poisoning
☎ Cholera	or their equivalent (1)	☎ <i>Staphylococcus aureus</i> disease, reduced or
☎ Congenital Syphilis	Influenza-associated death	resistant susceptibility to vancomycin (1)
COVID-19 (SARS-CoV-2 Coronavirus)	Influenza-associated hospitalization	<i>Staphylococcus aureus</i> methicillin-
COVID-19 Death	Legionellosis	resistant disease, invasive, community
COVID-19 Hospitalization	Listeriosis	acquired (3,8)
Cryptosporidiosis	Lyme disease	<i>Staphylococcus epidermidis</i> disease,
Cyclosporiasis	Malaria	reduced or resistant susceptibility
Dengue	☎ Measles	to vancomycin (1)
☎ Diphtheria	☎ Melioidosis	Syphilis
E-cigarette or vaping product use	☎ Meningococcal disease	Tetanus
associated lung injury (EVALI)	Mercury poisoning	Trichinosis
Eastern equine encephalitis virus infection	Mpox disease	☎ Tuberculosis
<i>Ehrlichia chaffeensis</i> infection	Multisystem inflammatory syndrome in	☎ Tularemia
<i>Escherichia coli</i> O157:H7 infection	children (MIS-C)	Typhoid fever
Gonorrhea	Mumps	Vaccinia disease
Group A Streptococcal disease, invasive (3)	Neonatal bacterial sepsis (6)	☎ Venezuelan equine encephalitis virus
Group B Streptococcal disease, invasive (3)	Occupational asthma	infection
<i>Haemophilus influenzae</i> disease, invasive (3)	☎ Outbreaks:	<i>Vibrio</i> infection (<i>parahaemolyticus</i> ,
Hansen's disease (Leprosy)	▪ Foodborne (involving ≥ 2 persons)	<i>vulnificus</i> , other)
Healthcare-associated Infections (4)	▪ Institutional	☎ Viral hemorrhagic fever
Hemolytic-uremic syndrome (5)	▪ Unusual disease or illness (7)	West Nile virus infection
Hepatitis A	Pertussis	☎ Yellow fever
	☎ Plague	Zika virus infection
	Pneumococcal disease, invasive (3)	
	☎ Poliomyelitis	

FOOTNOTES: (NOTE: a footnote was removed, and they have been renumbered)

- Report only to DPH.
- As described in the CDC case definition (<https://ndc.services.cdc.gov/>).
- Invasive disease: from sterile fluid (blood, CSF, pericardial, pleural, peritoneal, joint, or vitreous), bone, internal body sites, or other normally sterile site including muscle.
- Report HAIs according to current CMS pay-for-reporting or pay-for-performance requirements. Detailed instructions on the types of HAIs, facility types and locations, and methods of reporting are available on the DPH website.
- On request from the DPH and if adequate serum is available, send serum from patients with HUS to the DPH Laboratory for antibody testing.
- Clinical sepsis and blood or CSF isolate obtained from an infant ≤ 72 hours of age.
- Individual cases of "significant unusual illness" are also reportable.
- Community-acquired: infection present on admission to hospital, and person has no previous hospitalizations or regular contact with the health-care setting.

How to report: The PD-23 is the general disease reporting form and should be used if other specialized forms are not available. The PD-23 can be found on the DPH "Forms" webpage (<https://portal.ct.gov/DPH/Communications/Forms/Forms>). Specialized reporting forms are also available on the DPH "Forms" webpage and should be used for the following: National Healthcare Safety Network, Adult HIV Confidential Case Report, Chickenpox (Varicella) Case Report, Physician's Report of Occupational Disease, Sexually Transmitted Diseases (STD-23), Tuberculosis Surveillance Report, and the E-cigarette or Vaping Product Associated Lung Injury Case Report.

Telephone reports of Category 1 disease should be made to the local Director of Health for the town in which the patient resides, and to the Epidemiology and Emerging Infections Program (860-509-7994). Tuberculosis cases should be directly reported to the Tuberculosis Control Program (860-509-7722). For the name, address, or telephone number of the local Director of Health for a specific town contact the Office of Local Health Administration (860-509-7660).

For public health emergencies on evenings, weekends, and holidays call 860-509-8000.

REPORTABLE LABORATORY FINDINGS – 2023

The director of a clinical laboratory must report laboratory evidence suggestive of reportable diseases (see page 4 for additional information). The Laboratory Report of Significant Findings form (OL-15C) can be found on the DPH ["Forms" webpage](#).

Anaplasma phagocytophilum by PCR only
Babesia: IFA IgM (titer) _____ IgG (titer) _____
 Blood smear PCR Other _____
 microti *divergens* *duncani* Unspecified
Bordetella pertussis (titer) _____
 Culture (1) Non-pertussis *Bordetella* (1) (specify) _____
 DFA PCR
Borrelia burgdorferi (2)
Borrelia miyamotoi
California group virus (3) spp _____
Campylobacter (3) spp _____ Culture PCR EIA
Candida auris [report samples from all sites] (1)
Candida spp. [blood isolates only]: _____ (1,3)
Carbapenem-resistant *Acinetobacter baumannii* (CRAB) (1,4)
Carbapenem-resistant Enterobacteriaceae (CRE) (1,3,4)
Genus _____ spp _____
Carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) (1,4)
Carboxyhemoglobin \geq 5% _____ % COHb (2)
Chikungunya virus
Chlamydia trachomatis (test type) _____
Clostridium difficile (5)
Corynebacterium diphtheria (1)
Cryptosporidium spp (3) _____ PCR DFA EIA
 Microscopy Other: _____
Cyclospora spp (3) _____ PCR Microscopy Other: _____
Dengue virus
Eastern equine encephalitis virus
Ehrlichia chaffeensis PCR IgG titers \geq 1:128 only Culture
Enterotoxigenic *Escherichia coli* (ETEC) Culture PCR
Escherichia coli O157 (1) Culture PCR
Giardia spp (3) _____
Group A *Streptococcus*, invasive (1,4) Culture Other _____
Group B *Streptococcus*, invasive (1,4) Culture Other _____
Haemophilus ducreyi
Haemophilus influenzae, invasive (1,4) Culture Other _____
Hepatitis A virus (HAV): IgM anti-HAV (6) NAAT Positive (6)
ALT _____ Total Bilirubin _____ Not Done
Hepatitis B HBsAg Positive Negative (7)
 IgM anti-HBc HBsAg (2) HBV DNA (2)
anti-HBs (7) Positive (titer) _____ Negative
Hepatitis C virus (HCV) (8) Antibody _____
 PCR/NAAT/RNA Genotype specify _____
Herpes simplex virus (infants \leq 60 days of age)
 Culture PCR IFA Ag detection
HIV Related Testing (report only to the State) (9)
 Detectable Screen (IA)
Antibody Confirmation (WB/IFA/Type-diff) (9)
HIV 1 Positive Neg/Ind HIV 2 Positive Neg/Ind
 HIV NAAT (or qualitative RNA) Detectable Not Detectable
 HIV Viral Load (all results) (9) _____ copies/mL
 HIV genotype (9)
 CD4 count: _____ cells/uL; _____ % (9)
HPV (report only to the State) (10)
Biopsy proven CIN 2 CIN 3 AIS
or their equivalent, (specify) _____
Influenza virus: (report only to State) Rapid antigen (2) RT-PCR
 Type A Type B Type Unknown
 Subtype _____
Lead poisoning (blood lead \geq 3.5 μ g/dL < 48 hrs; 0-3.5 μ g/dL monthly) (11)
 Finger stick level _____ μ g/dL Venous level _____ μ g/dL
Legionella spp (1)
 Culture DFA Ag positive
 Four-fold serologic change (titers) _____
Listeria monocytogenes (1) Culture PCR
Mercury poisoning
 Urine \geq 35 μ g/g creatinine _____ μ g/g
 Blood \geq 15 μ g/L _____ μ g/L
Monkeypox virus PCR IgM anti-MPXV Sequencing
 Orthopoxvirus PCR IHC Sequencing
 Non-variola orthopoxvirus PCR
Mumps virus (12) (titer) _____ PCR
Mycobacterium leprae
Mycobacterium tuberculosis Related Testing (1)
AFB Smear Positive Negative
If positive Rare Few Numerous
NAAT Positive Negative Indeterminate
Culture *Mycobacterium tuberculosis*
 Non-TB mycobacterium. (specify *M.* _____)
Neisseria gonorrhoeae (test type) _____
Neisseria meningitidis, invasive (1,4)
 Culture Other _____
Neonatal bacterial sepsis (3,13) Genus _____ spp _____
Plasmodium (1,3) spp _____
Poliovirus
Powassan virus
Rabies virus
Rickettsia rickettsia PCR IgG titers \geq 1:128 only Culture
Respiratory syncytial virus (2)
Rubella virus (12) (titer) _____
Rubeola virus (Measles) (12) (titer) _____ PCR
St. Louis encephalitis virus
Salmonella (1,3) (serogroup & type) _____ Culture PCR
SARS-CoV (1) IgM/IgG
 PCR Other _____
SARS-CoV-2 PCR Antigen
Shiga toxin (1) Stx1 Stx2 Type Unknown
 PCR EIA
Shigella (1,3) (serogroup/spp) _____ Culture PCR
Staphylococcus aureus, invasive (4) Culture Other _____
 methicillin-resistant methicillin-sensitive
Staphylococcus aureus, vancomycin MIC \geq 4 μ g/mL (1)
MIC to vancomycin _____ μ g/mL
Staphylococcus epidermidis, vancomycin MIC \geq 32 μ g/mL (1)
MIC to vancomycin _____ μ g/mL
Streptococcus pneumoniae
 Culture (1,4) Urine antigen Other (4) _____
Treponema pallidum RPR (titer) _____ FTA EIA
 VDRL (titer) _____ TPPA
Trichinella
Varicella-zoster virus
 Culture PCR DFA Other _____
Vibrio (1,3) spp _____ Culture PCR
West Nile virus
Yellow fever virus
Yersinia, not *pestis* (1,3) spp _____ Culture PCR
Zika virus
BIOTERRORISM AGENTS at first clinical suspicion (14)
Bacillus anthracis (1) Venezuelan equine encephalitis virus
Burkholderia mallei (1) *Brucella* spp (1)
Clostridium botulinum *Burkholderia pseudomallei* (1)
Francisella tularensis *Coxiella burnetii*
Staphylococcus aureus - enterotoxin B Ricin
Variola virus (1) *Yersinia pestis* (1)
Viral agents of hemorrhagic fevers

- Send isolate/specimen to DPH Laboratory. Send laboratory report (electronic or paper) on first identification of an organism. For CRE/CRAB, and CRPA, send laboratory report if carbapenem resistance is suggested by laboratory antimicrobial testing; include antimicrobial test results with report. For GBS, send isolate for cases <1 year of age. For *Salmonella*, *Shigella*, *Vibrio*, and *Yersinia* (not *pestis*) tested by non-culture methods, send isolate if available; send stool specimen if no isolate available. For Shiga toxin-related disease, send positive broth or stool specimen.
- Only laboratories with electronic file reporting are required to report positive results.
- Specify species/serogroup/serotype.
- Sterile site: sterile fluids (blood, CSF, pericardial, pleural, peritoneal, joint, or vitreous), bone, internal body site (lymph node, brain, heart, liver, spleen, kidney, pancreas, or ovary), or other normally sterile site including muscle. For CRE, CRAB, and CRPA also include urine or sputum; for CRAB and CRPA also include wounds.
- Upon request from the DPH, report all *C. difficile* positive stool samples.
- Report peak ALT and Total Bilirubin results if conducted within one week of HAV positive test, if available. Otherwise, check "Not Done".
- Negative HBsAg and all anti-HBs results only reportable for children \leq 2 years old.
- Report positive Antibody, and all RNA and Genotype results. Negative RNA results only reportable by electronic reporting.
- Report all positive HIV antibody, antigen, viral load, and qualitative NAAT results. HIV genotype (DNA sequence) and all CD4 results are only reportable by electronic file reporting.
- Upon request from the DPH, send fixed tissue from the diagnostic specimen for HPV typing.
- Report results \geq 3.5 μ g/dL within 48 hours to the Local Health Department and DPH; submit ALL lead results at least monthly to DPH only.
- Report all IgM positive titers, only report IgG titers considered significant by laboratory performing the test.
- Report all bacterial isolates from blood or CSF from infants \leq 72 hours of age.
- Call the DPH, weekdays 860-509-7994; evenings, weekends, and holidays 860-509-8000.

Persons Required to Report Reportable Diseases, Emergency Illnesses and Health Conditions

1. Every health care provider who treats or examines any person who has or is suspected to have a reportable disease, emergency illness or health condition shall report the case to the local director of health or other health authority within whose jurisdiction the patient resides and to the Department of Public Health.
2. If the case or suspected case of reportable disease, emergency illness or health condition is in a health care facility, the person in charge of such facility shall ensure that reports are made to the local director of health and the Department of Public Health. The person in charge shall designate appropriate infection control or record keeping personnel for this purpose.
3. If the case or suspected case of reportable disease, emergency illness or health condition is not in a health care facility, and if a health care provider is not in attendance or is not known to have made a report within the appropriate time, such report of reportable disease, emergency illness or health condition shall be made to the local director of health or other health authority within whose jurisdiction the patient lives and the Department of Public Health by:
 - a. the administrator serving a public or private school or day care center attended by any person affected or apparently affected with such disease, emergency illness or health condition;
 - b. the person in charge of any camp;
 - c. the master or any other person in charge of any vessel lying within the jurisdiction of the state;
 - d. the master or any other person in charge of any aircraft landing within the jurisdiction of the state;
 - e. the owner or person in charge of any establishment producing, handling, or processing dairy products, other food or non-alcoholic beverages for sale or distribution;
 - f. morticians and funeral directors.

Persons Required to Report Reportable Laboratory Findings

The director of a laboratory that receives a primary specimen or sample, which yields a reportable laboratory finding, shall be responsible for reporting such findings within 48 hours to the local director of health of the town in which the affected person normally resides. In the absence of such information, the reports should go to the town from which the specimen originated and to the Department of Public Health. Reports must include name, address, contact phone number, date of birth, race, ethnicity, gender, and occupation of patient.

IMPORTANT NOTICE

The Reportable Disease Confidential Case Report Form PD-23 can be used to report conditions on the current list, unless there is a specialized form or other authorized method. Reporting forms can be found at: (<https://portal.ct.gov/DPH/Communications/Forms/Forms>). Please follow these guidelines when submitting written reports:

- Forms must include name, address, and phone number of person reporting and healthcare provider, infectious agent, test method, date of onset of illness, and name, address, date of birth, race, ethnicity, gender, and occupation of patient.
- Send the completed form to DPH via fax (860-920-3131)

Connecticut Department of Public Health

Manisha Juthani, MD
Commissioner of Public Health

Lynn Sosa, MD
State Epidemiologist

Infectious Diseases Programs

Epidemiology and Emerging Infections
860-509-7994

Healthcare Associated Infections & Antimicrobial Resistance
860-509-7995

HIV & Viral Hepatitis
860-509-7900

Immunizations
860-509-7929

Sexually Transmitted Diseases
860-509-7920

Tuberculosis Control
860-509-7722

The Connecticut Epidemiologist Newsletter - (Telecommunications Relay Service 7-1-1)

Editor: Susan Petit, MPH

Assistant Editor: Amanda Durante, PhD, MSc

Assistant Editor/Producer: Chris Heneghan, MPH